arrow
D

David Hudesman

University System of Maryland
H指数:29
被引数:3,703

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessing Inflammation and Predicting Relapse in Ulcerative Colitis is More Accurate When Performed by IBD Specialized Gastroenterologists

评估溃疡性结肠炎炎症和预测复发的准确性,在由IBD专业胃肠病学家进行时更高。

2025-12-010
PRE
Presence of Spondyloarthritis Symptoms in IBD Is Associated With Higher Medication Use and Worse-Long Term Outcomes

炎症性肠病中脊柱关节炎症状的存在与更高的药物使用和更差的长期预后相关。

2025-10-010
PRE
Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease

老年炎症性肠病患者中乌司奴单抗和维多珠单抗的安全性与有效性

2025-09-160
PRE
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
2024-03-010
OAAI
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program

在溃疡性结肠炎OCTAVE临床项目中,托法替尼对患者报告的直肠出血、大便次数和健康相关生活质量的长期改善

2022-11-070
OAAI
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
2022-09-3027
PRE
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
2022-04-135
OA
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
2022-01-0136
OAAI
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease
2021-12-0117
OA